Does Concurrent Cholestasis Alter the Prognostic Value of Preoperatively Elevated CA19-9 Serum Levels in Patients with Pancreatic Head Adenocarcinoma?

BACKGROUND: Pancreatic adenocarcinoma (PDAC) patients with preoperative carbohydrate antigen 19-9 (CA19-9) serum levels higher than 500 U/ml are classified as biologically borderline resectable (BR-B). To date, the impact of cholestasis on preoperative CA19-9 serum levels in these patients has remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Anger, Friedrich, Lock, Johan Friso, Klein, Ingo, Hartlapp, Ingo, Wiegering, Armin, Germer, Christoph-Thomas, Kunzmann, Volker, Löb, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Pancreatic Tumors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640457/
https://www.ncbi.nlm.nih.gov/pubmed/36094690
http://dx.doi.org/10.1245/s10434-022-12460-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640457/
https://www.ncbi.nlm.nih.gov/pubmed/36094690
http://dx.doi.org/10.1245/s10434-022-12460-w

Ejemplares similares